Revolution Medicines (NASDAQ:RVMD) Announces Quarterly Earnings Results

Revolution Medicines (NASDAQ:RVMD) issued its quarterly earnings data on Wednesday. The company reported ($3.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.04) by ($1.02), FiscalAI reports. During the same period in the previous year, the business posted ($1.31) EPS.

Here are the key takeaways from Revolution Medicines’ conference call:

• Positive Sentiment: Daraxonrasib’s Phase III RASolute 302 results in previously treated metastatic pancreatic cancer showed statistically significant improvements in overall survival, progression-free survival, and quality-of-life measures versus chemotherapy, with a manageable safety profile.
• Positive Sentiment: The FDA accepted Revolution Medicines’ NDA for daraxonrasib in pancreatic cancer, while the EMA began an expedited phased review; the company has also established expanded access at sites in nearly all U.S. states and Puerto Rico, providing treatment to more than 2,000 eligible patients.
• Positive Sentiment: Early combination data in first-line pancreatic and lung cancer were encouraging, including response rates of 82% for zoldonrasib plus chemotherapy in pancreatic cancer, 82% for zoldonrasib plus standard of care in G12D lung cancer, and 85% for elironrasib plus standard of care in G12C lung cancer.
• Positive Sentiment: The company is broadening its registrational pipeline, with Phase III trials underway or planned for multiple pancreatic and lung cancer settings, including RASolute 309, RASolve 307, and RASolve 308; initial Phase III lung cancer data are expected in 2027.
• Negative Sentiment: Revolution Medicines raised 2026 GAAP operating expense guidance to $2.1 billion-$2.2 billion as it accelerates manufacturing, clinical development, and commercial preparations; second-quarter net loss widened to $644 million from $248 million a year earlier.

Revolution Medicines Price Performance

Shares of NASDAQ:RVMD traded up $7.73 during trading on Friday, reaching $205.54. 1,126,919 shares of the company traded hands, compared to its average volume of 3,130,105. The firm has a market capitalization of $43.70 billion, a PE ratio of -23.33 and a beta of 1.39. Revolution Medicines has a 52 week low of $34.14 and a 52 week high of $203.99. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.19. The company’s 50 day moving average is $175.71 and its two-hundred day moving average is $136.99.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Piper Sandler increased their target price on Revolution Medicines to $172.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Revolution Medicines in a research note on Friday, July 17th. Needham & Company LLC upped their price objective on Revolution Medicines from $236.00 to $240.00 and gave the company a “buy” rating in a report on Thursday. Evercore reiterated an “outperform” rating and set a $230.00 price objective on shares of Revolution Medicines in a research report on Thursday. Finally, Truist Financial lifted their target price on Revolution Medicines from $179.00 to $210.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $153.05.

Insider Buying and Selling

In related news, insider Mark A. Goldsmith sold 10,020 shares of Revolution Medicines stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $156.12, for a total value of $1,564,322.40. Following the transaction, the insider directly owned 267,330 shares of the company’s stock, valued at $41,735,559.60. This trade represents a 3.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Sushil Patel sold 5,580 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $187.99, for a total transaction of $1,048,984.20. Following the transaction, the director owned 21,656 shares of the company’s stock, valued at approximately $4,071,111.44. This represents a 20.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 132,497 shares of company stock worth $21,470,486. 7.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Revolution Medicines

Several hedge funds and other institutional investors have recently made changes to their positions in RVMD. Global Retirement Partners LLC boosted its position in Revolution Medicines by 1,002.8% in the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock valued at $32,000 after buying an additional 361 shares in the last quarter. Arax Advisory Partners acquired a new position in shares of Revolution Medicines during the fourth quarter worth $38,000. Los Angeles Capital Management LLC bought a new position in shares of Revolution Medicines in the 4th quarter valued at $59,000. Empowered Funds LLC bought a new position in shares of Revolution Medicines in the 4th quarter valued at $77,000. Finally, Danske Bank A S acquired a new stake in shares of Revolution Medicines during the 3rd quarter valued at $98,000. 94.34% of the stock is owned by institutional investors.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.